MARKET

SRTS

SRTS

Sensus Healthcare Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.72
-0.11
-1.25%
After Hours: 8.72 0 0.00% 16:10 05/20 EDT
OPEN
8.92
PREV CLOSE
8.83
HIGH
9.02
LOW
8.51
VOLUME
102.65K
TURNOVER
221.35K
52 WEEK HIGH
11.96
52 WEEK LOW
3.075
MARKET CAP
145.43M
P/E (TTM)
6.78
1D
5D
1M
3M
1Y
5Y
Wall Street Analysts Think Sensus Healthcare, Inc. (SRTS) Could Surge 53%: Read This Before Placing a Bet
The consensus price target hints at a 52.9% upside potential for Sensus Healthcare, Inc. (SRTS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will...
Zacks · 22h ago
Sensus Healthcare to Participate in the H.C. Wainwright Global Investment Conference
BOCA RATON, Fla, May 18, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditio...
GlobeNewswire · 2d ago
Shareholders Would Enjoy A Repeat Of Sensus Healthcare's (NASDAQ:SRTS) Recent Growth In Returns
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...
Simply Wall St. · 05/12 10:24
ChemoCentryx, iRhythm top healthcare gainers; Joint, Endo lead losers' pack
Gainers: ChemoCentryx (CCXI) +19%. iRhythm Technologies (IRTC) +16%. Jounce Therapeutics (JNCE) +15%. Grifols (GRFS) +9%. Sensus Healthcare (SRTS) +8%. Losers: Joint (JYNT) -46%. Endo International (ENDP) -34%. Guardant Health (GH) -26%. Gain Therapeutics ...
Seekingalpha · 05/06 14:05
BRIEF-Sensus Healthcare Q1 Revenue Rose 237% To $10.3 Million
reuters.com · 05/05 23:04
Sensus Healthcare, Inc. (SRTS) Beats Q1 Earnings and Revenue Estimates
Sensus Healthcare, Inc. (SRTS) delivered earnings and revenue surprises of 233.33% and 65.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/05 22:55
Sensus Healthcare GAAP EPS of $0.97 beats by $0.64, revenue of $10.3M beats by $3.57M
Sensus Healthcare press release (NASDAQ:SRTS): Q1 GAAP EPS of $0.97 beats by $0.64. Revenue of $10.3M (+232.3% Y/Y) beats by $3.57M. Shares +3.5%.
Seekingalpha · 05/05 20:40
Sensus Healthcare to Host First Quarter 2022 Financial Results and Business Update Conference Call on May 5, 2022
BOCA RATON, Fla, April 21, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management wi...
GlobeNewswire · 04/21 12:00
More
No Data
Learn about the latest financial forecast of SRTS. Analyze the recent business situations of Sensus Healthcare Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average SRTS stock price target is 14.30 with a high estimate of 17.00 and a low estimate of 12.00.
High17.00
Average14.30
Low12.00
Current 8.72
EPS
Actual
Estimate
0.190.450.700.96
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 60
Institutional Holdings: 4.73M
% Owned: 28.36%
Shares Outstanding: 16.68M
TypeInstitutionsShares
Increased
22
890.29K
New
18
1.43M
Decreased
10
135.00K
Sold Out
6
52.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.36%
Healthcare Equipment & Supplies
+0.36%
Key Executives
Chairman/Chief Executive Officer/Co-Founder/Director
Joseph Sardano
President/General Counsel
Michael Sardano
Chief Financial Officer
Javier Rampolla
Chief Operating Officer
Nicolas Soro
Chief Technology Officer
Yonatan Vainer
Director
Megan Cornish
Non-Executive Director
Anthony Petrelli
Non-Executive Independent Director
John Heinrich
Non-Executive Independent Director
William McCall
Non-Executive Independent Director
Samuel O'Rear
No Data
No Data
About SRTS
Sensus Healthcare, Inc. is a medical device company. The Company is focused on providing non-invasive treatments for both oncological and non-oncological skin conditions. The Company uses a low-energy X-ray technology known as superficial radiation therapy (SRT). The Company incorporated SRT into its portfolio of treatment devices: the SRT-100, SRT-100 Plus and SRT-100 Vision. The Company's product, SRT-100, is a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its other two products, such as SRT-100 Plus and SRT-100 Vision provides customers with additional options compared to the SRT-100 base model.

Webull offers kinds of Sensus Healthcare Inc stock information, including NASDAQ:SRTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRTS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SRTS stock methods without spending real money on the virtual paper trading platform.